Identification
- Summary
Ammonium lactate is an inorganic compound used for the symptomatic treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions.
- Brand Names
- Lac-hydrin, Ultravate X Ointment
- Generic Name
- Ammonium lactate
- DrugBank Accession Number
- DB06768
- Background
Ammonium lactate is the ammonium salt of lactic acid.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Ammonium lactate (DB06768)
- Weight
- Average: 107.1085
Monoisotopic: 107.058243159 - Chemical Formula
- C3H9NO3
- Synonyms
- Ammonium (+-)-lactate
- Ammonium lactate
- Lactic acid ammonium salt
- External IDs
- E328
Pharmacology
- Indication
For the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Lactic acid is an alpha-hydroxy acid. It is a normal constituent of tissues and blood. The alpha-hydroxy acids (and their salts) may act as humectants when applied to the skin. This property may influence hydration of the stratum corneum. In addition, lactic acid, when applied to the skin, may act to decrease corneocyte cohesion.
- Mechanism of action
Unknown.
- Absorption
In vitro study of percutaneous absorption of ammonium lactate lotion, 12% using human cadaver skin indicates that approximately 5.8% of the material was absorbed after 68 hours.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The oral administration of Lac-Hydrin to rats and mice showed this drug to be practically non-toxic (LD50 > 15 mL/kg).
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Lactic acid unknown 3B8D35Y7S4 50-21-5 JVTAAEKCZFNVCJ-UHFFFAOYSA-N - International/Other Brands
- Amlactin
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Lac Hydrin Cream Cream 120 mg/1g Topical Sun Pharmaceutical Industries, Inc. 2009-03-16 2014-02-28 US 
Lac-Hydrin Lotion 120 mg/1g Topical Ranbaxy, Inc 2008-01-28 Not applicable US Lac-Hydrin Cream 120 mg/1g Topical Bristol Myers Squibb Pharma Company 2009-06-01 2012-10-15 US Lac-Hydrin Lotion 120 mg/1g Topical Physicians Total Care, Inc. 2008-08-15 2012-06-30 US Lac-Hydrin Lotion 120 mg/1g Topical Sun Pharmaceutical Industries Limited 2008-08-15 2008-08-15 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ammonium Lactate Cream 12 g/100g Topical REMEDYREPACK INC. 2019-11-25 Not applicable US Ammonium Lactate Cream 120 mg/1g Topical Goldline Laboratories, Inc. 2009-02-28 2009-03-01 US Ammonium Lactate Lotion 12 g/100g Topical bryant ranch prepack 2006-06-20 Not applicable US Ammonium Lactate Lotion 12 g/100g Topical Padagis Israel Pharmaceuticals Ltd 2006-06-20 Not applicable US Ammonium Lactate Lotion 120 mg/1g Topical Taro Pharmaceuticals U.S.A., Inc. 2004-05-28 Not applicable US Ammonium Lactate Lotion 120 mg/1g Topical A-S Medication Solutions 2004-05-28 Not applicable US Ammonium Lactate Lotion 12 g/100g Topical bryant ranch prepack 2006-06-20 Not applicable US Ammonium Lactate Cream 12 g/100g Topical Actavis Pharma, Inc. 2012-06-05 2016-03-31 US Ammonium Lactate Cream 12 g/100g Topical Padagis Israel Pharmaceuticals Ltd 2006-08-16 Not applicable US Ammonium Lactate Cream 120 mg/1g Topical Taro Pharmaceuticals U.S.A., Inc. 2003-04-10 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ammonium Lactate Cream 17 g/1g Topical Nnodum Pharmaceuticals 2007-12-30 Not applicable US Ammonium Lactate Lotion 17 g/1g Topical Nnodum Pharmaceuticals 2007-12-30 Not applicable US Geri-Hydrolac Cream 12 g/100g Topical GERITREX CORP 2013-06-25 Not applicable US Geri-Hydrolac Lotion 12 g/100g Topical GERITREX CORP 2013-05-10 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Quinosone Ammonium lactate (120 mg/1g) + Mometasone furoate (1 mg/1g) Kit Topical V2 Pharma, LLC 2019-06-03 Not applicable US Ultravate X Ammonium lactate (100 mg/1g) + Ulobetasol propionate (0.50 mg/1g) Kit Topical Ranbaxy Inc. 2012-07-01 Not applicable US Ultravate X Ammonium lactate (100 mg/1g) + Ulobetasol propionate (0.5 mg/1g) Kit Topical Sun Pharmaceutical Industries, Inc. 2012-07-09 2017-08-31 US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as carboxylic acid salts. These are ionic derivatives of carboxylic acid.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Carboxylic acid derivatives
- Direct Parent
- Carboxylic acid salts
- Alternative Parents
- Secondary alcohols / Monocarboxylic acids and derivatives / Carboxylic acids / Organic zwitterions / Organic salts / Organic oxides / Organic nitrogen compounds / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Alcohol / Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid salt / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Organic nitrogen compound / Organic oxide / Organic oxygen compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 67M901L9NQ
- CAS number
- 515-98-0
- InChI Key
- RZOBLYBZQXQGFY-UHFFFAOYSA-N
- InChI
- InChI=1S/C3H6O3.H3N/c1-2(4)3(5)6;/h2,4H,1H3,(H,5,6);1H3
- IUPAC Name
- ammonium 2-hydroxypropanoate
- SMILES
- [NH4+].CC(O)C([O-])=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015671
- KEGG Drug
- D02920
- PubChem Compound
- 62358
- PubChem Substance
- 175427089
- ChemSpider
- 56149
- 215247
- ChEMBL
- CHEMBL1200747
- PharmGKB
- PA165958400
- Wikipedia
- Ammonium_lactate
- FDA label
- Download (14.2 KB)
- MSDS
- Download (46.8 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Psoriasis Vulgaris (Plaque Psoriasis) 1 4 Completed Treatment Stable Plaque Psoriasis 1 3 Completed Treatment Dry Skin 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Cream Topical 12 g/100g Cream Topical 120 mg/1g Cream Topical 17 g/1g Lotion Topical 12 g/100g Lotion Topical 17 g/1g Lotion Topical 120 mg/1g Kit Topical - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 866.0 mg/mL ALOGPS logP -0.51 ALOGPS logP -0.47 Chemaxon logS 0.91 ALOGPS pKa (Strongest Acidic) 3.78 Chemaxon pKa (Strongest Basic) -3.7 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 60.36 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 29.68 m3·mol-1 Chemaxon Polarizability 7.65 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.7873 Blood Brain Barrier + 0.7656 Caco-2 permeable - 0.7876 P-glycoprotein substrate Non-substrate 0.7911 P-glycoprotein inhibitor I Non-inhibitor 0.9869 P-glycoprotein inhibitor II Non-inhibitor 0.9581 Renal organic cation transporter Non-inhibitor 0.952 CYP450 2C9 substrate Non-substrate 0.8121 CYP450 2D6 substrate Non-substrate 0.9016 CYP450 3A4 substrate Non-substrate 0.7749 CYP450 1A2 substrate Non-inhibitor 0.9606 CYP450 2C9 inhibitor Non-inhibitor 0.9147 CYP450 2D6 inhibitor Non-inhibitor 0.9687 CYP450 2C19 inhibitor Non-inhibitor 0.9614 CYP450 3A4 inhibitor Non-inhibitor 0.9755 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9734 Ames test Non AMES toxic 0.9357 Carcinogenicity Non-carcinogens 0.5528 Biodegradation Ready biodegradable 0.9862 Rat acute toxicity 1.5255 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.986 hERG inhibition (predictor II) Non-inhibitor 0.9698
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at September 14, 2010 16:21 / Updated at February 21, 2021 18:52